{"id":"hymecromone","rwe":[{"pmid":"40774020","year":"2025","title":"The potential of 4-Methylumbelliferone to be repurposed for treating liver fibrosis.","finding":"","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","studyType":"Clinical Study"},{"pmid":"40626973","year":"2025","title":"Logic-Gated Release of a Dual Payload from a β-Lactam Mechanophore with a Rotaxane Actuator.","finding":"","journal":"Angewandte Chemie (International ed. in English)","studyType":"Clinical Study"},{"pmid":"40475534","year":"2025","title":"The potential of 4-Methylumbelliferone to be repurposed for treating liver fibrosis.","finding":"","journal":"bioRxiv : the preprint server for biology","studyType":"Clinical Study"},{"pmid":"40451287","year":"2025","title":"Randomised, placebo-controlled trial of oral hymecromone in adults with pulmonary hypertension.","finding":"","journal":"Thorax","studyType":"Clinical Study"},{"pmid":"40394974","year":"2025","title":"Study of the Photoinduced Fate of Selected Contaminants in Surface Waters by HPLC-HRMS.","finding":"","journal":"Rapid communications in mass spectrometry : RCM","studyType":"Clinical Study"}],"tags":[{"label":"hymecromone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Carbonic anhydrase 9","category":"target"},{"label":"CA9","category":"gene"},{"label":"HSD17B3","category":"gene"},{"label":"CA12","category":"gene"},{"label":"A05AX02","category":"atc"},{"label":"Active","category":"status"},{"label":"Indicators and Reagents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"bilcolic","offLabel":[],"synonyms":["hymecromone","imecromone","cantabilin","cholestil","cholspasmin","mendiaxon","bilcolic","bilicante"],"timeline":[],"approvals":[],"brandName":"Bilcolic","ecosystem":[],"mechanism":{"target":"Induced myeloid leukemia cell differentiation protein Mcl-1, Testosterone 17-beta-dehydrogenase 3, Aldose reductase","targets":[{"gene":"CA9","source":"DrugCentral","target":"Carbonic anhydrase 9","protein":"Carbonic anhydrase 9"},{"gene":"HSD17B3","source":"DrugCentral","target":"Testosterone 17-beta-dehydrogenase 3","protein":"Testosterone 17-beta-dehydrogenase 3"},{"gene":"CA12","source":"DrugCentral","target":"Carbonic anhydrase 12","protein":"Carbonic anhydrase 12"},{"gene":"MCL1","source":"DrugCentral","target":"Induced myeloid leukemia cell differentiation protein Mcl-1","protein":"Induced myeloid leukemia cell differentiation protein Mcl-1"},{"gene":"AKR1B1","source":"DrugCentral","target":"Aldose reductase","protein":"Aldose reductase"},{"gene":"MAOB","source":"DrugCentral","target":"Amine oxidase [flavin-containing] B","protein":"Amine oxidase [flavin-containing] B"}],"modality":"Small Molecule","drugClass":"hymecromone","explanation":"Think of carbonic anhydrase 9 like a pump that helps move fluid and electrolytes in and out of cells. By blocking this pump, Bilcolic helps reduce swelling and excess fluid in the body. This can be beneficial for people with conditions like edema or glaucoma.","oneSentence":"Bilcolic works by inhibiting the enzyme carbonic anhydrase 9, which helps regulate fluid and electrolyte balance in the body.","technicalDetail":"Bilcolic exerts its effects by competitively inhibiting the zinc-dependent activity of carbonic anhydrase 9, thereby reducing the enzyme's ability to catalyze the reversible hydration of carbon dioxide to bicarbonate and protons."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1401","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=HYMECROMONE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HYMECROMONE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T14:57:38.064634","biosimilars":[],"competitors":[{"drugName":"maralixibat hydrochloride","drugSlug":"maralixibat-hydrochloride","fdaApproval":"2021-09-29","relationship":"same-class"},{"drugName":"odevixibat","drugSlug":"odevixibat","fdaApproval":"2021-07-20","patentExpiry":"Nov 8, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"hymecromone","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"maralixibat-hydrochloride","brandName":"maralixibat hydrochloride","genericName":"maralixibat hydrochloride","approvalYear":"2021","relationship":"same-class"},{"drugId":"odevixibat","brandName":"odevixibat","genericName":"odevixibat","approvalYear":"2021","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06325696","phase":"PHASE2","title":"H01 in Adults With Interstitial Lung Disease (The SOLIS Study)","status":"RECRUITING","sponsor":"National Institute of Environmental Health Sciences (NIEHS)","startDate":"2025-05-05","conditions":["Interstitial Lung Disease","Idiopathic Pulmonary Fibrosis","Lung Diseases, Interstitial"],"enrollment":37,"completionDate":"2027-12-31"},{"nctId":"NCT05295680","phase":"PHASE2","title":"Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.","status":"RECRUITING","sponsor":"Aparna Goel","startDate":"2023-05-10","conditions":["Primary Sclerosing Cholangitis"],"enrollment":24,"completionDate":"2027-12"},{"nctId":"NCT05128929","phase":"PHASE2","title":"Investigation of H01 in Adults With Pulmonary Hypertension Including Interstitial Lung Disease (The SATURN Study).","status":"COMPLETED","sponsor":"Stanford University","startDate":"2022-04-01","conditions":["Pulmonary Hypertension"],"enrollment":17,"completionDate":"2023-09-29"},{"nctId":"NCT05386420","phase":"NA","title":"A Safety and Efficacy Study of Hymecromone Tablets for the Treatment of Patients With COVID-19.","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-05-23","conditions":["COVID-19"],"enrollment":304,"completionDate":"2022-11-15"},{"nctId":"NCT02780752","phase":"PHASE1","title":"A Study of Oral Hymecromone and Hyaluronan Synthesis","status":"COMPLETED","sponsor":"Paul Bollyky","startDate":"2020-12-01","conditions":["Healthy","Respiratory Disease"],"enrollment":12,"completionDate":"2021-05-10"},{"nctId":"NCT00225537","phase":"PHASE2","title":"4-Methylumbelliferone as a Treatment for Chronic HBV/HCV","status":"UNKNOWN","sponsor":"MTmedical Institute of Health","startDate":"2005-09","conditions":["Chronic Hepatitis C","Chronic Hepatitis B"],"enrollment":160,"completionDate":"2007-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NUI":"N0000167012","NDDF":"005482","UNII":"3T5NG4Q468","CHEBI":"CHEBI:17224","INN_ID":"1891","RXNORM":"5556","UMLSCUI":"C0020411","ChEMBL_ID":"CHEMBL12208","KEGG_DRUG":"D00170","DRUGBANK_ID":"DB07118","PDB_CHEM_ID":"4MU","PUBCHEM_CID":"5280567","MESH_DESCRIPTOR_UI":"D006923"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":73,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"A05AX02","allCodes":["A05AX02"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Sep","pmid":"40774020","title":"The potential of 4-Methylumbelliferone to be repurposed for treating liver fibrosis.","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"date":"2025 Sep 8","pmid":"40626973","title":"Logic-Gated Release of a Dual Payload from a β-Lactam Mechanophore with a Rotaxane Actuator.","journal":"Angewandte Chemie (International ed. in English)"},{"date":"2025 May 23","pmid":"40475534","title":"The potential of 4-Methylumbelliferone to be repurposed for treating liver fibrosis.","journal":"bioRxiv : the preprint server for biology"},{"date":"2025 Aug 15","pmid":"40451287","title":"Randomised, placebo-controlled trial of oral hymecromone in adults with pulmonary hypertension.","journal":"Thorax"},{"date":"2025 Sep 15","pmid":"40394974","title":"Study of the Photoinduced Fate of Selected Contaminants in Surface Waters by HPLC-HRMS.","journal":"Rapid communications in mass spectrometry : RCM"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bilcolic (Hymecromone) is a small molecule drug that targets carbonic anhydrase 9, a key enzyme involved in the regulation of fluid and electrolyte balance. It is classified as a hymecromone, a type of carbonic anhydrase inhibitor. However, there is limited information available on its commercial status, approved indications, and pharmacokinetic properties. Further research is needed to fully understand its clinical applications and safety profile. As a result, its current status in the pharmaceutical market is unclear.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}